Baker Avenue Asset Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Baker Avenue Asset Management’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-7,010	Closed	-$254K	–	196
2015 Q2	$254K	Sell	7,010 -1,110	-14%	-$38.2K	0.03%	213
2015 Q1	$267K	Buy	+8,120	New	+$248K	0.04%	195

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Baker Avenue Asset Management's BBC Position: Q3 2015 in Review

Baker Avenue Asset Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2015, closing a stake of 7,010 shares — an estimated $254K sold.

Baker Avenue Asset Management first reported a position in BBC in Q1 2015 and held it in 2 quarters. The position peaked at $267K in Q1 2015. 16 funds tracked by Wall St. Rank hold BBC as of Q3 2015.

Baker Avenue Asset Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2015 after selling out during the quarter.
Baker Avenue Asset Management sold 7,010 Virtus Biotech Clinical Trials ETF shares in Q3 2015, an estimated $254K.
Baker Avenue Asset Management first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2015 and held it in 2 quarters.
Baker Avenue Asset Management's Virtus Biotech Clinical Trials ETF position peaked at $267K in Q1 2015.
16 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2015.

Based on Baker Avenue Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.